Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kristine D Harper

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Current Medical Research and Opinion|October 7, 2006
Comments on Initial experience with teriparatide in the United StatesKristine D Harper, John H Krege, Robert Marcus, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|November 30, 2006
Osteosarcoma and teriparatide?Kristine D Harper, John H Krege, Robert Marcus, et al.
Archives of Internal Medicine|May 22, 2002
Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosisMichael Maricic, Jonathan D Adachi, Somnath Sarkar, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|January 5, 2002
Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapySomnath Sarkar, Bruce H Mitlak, Mayme Wong, et al.
Diabetes, Obesity & Metabolism|October 22, 2016
Effects of once-weekly dulaglutide on kidney function in patients with type 2 diabetes in phase II and III clinical trialsKatherine R Tuttle, T Dwight McKinney, Jaime A Davidson, et al.
Diabetes Care|March 12, 2017
Assessment of Pancreas Safety in the Development Program of Once-Weekly GLP-1 Receptor Agonist DulaglutideMichael A Nauck, Jean-Louis Frossard, Jamie S Barkin, et al.
JAMA|February 20, 2002
Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trialElizabeth Barrett-Connor, Deborah Grady, Andreas Sashegyi, et al.
The Journal of Clinical Endocrinology and Metabolism|August 6, 2002
Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trialPierre D Delmas, Kristine E Ensrud, Jonathan D Adachi, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Current Medical Research and Opinion|October 7, 2006
Comments on Initial experience with teriparatide in the United StatesKristine D Harper, John H Krege, Robert Marcus, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|November 30, 2006
Osteosarcoma and teriparatide?Kristine D Harper, John H Krege, Robert Marcus, et al.
Archives of Internal Medicine|May 22, 2002
Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosisMichael Maricic, Jonathan D Adachi, Somnath Sarkar, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|January 5, 2002
Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapySomnath Sarkar, Bruce H Mitlak, Mayme Wong, et al.
Diabetes, Obesity & Metabolism|October 22, 2016
Effects of once-weekly dulaglutide on kidney function in patients with type 2 diabetes in phase II and III clinical trialsKatherine R Tuttle, T Dwight McKinney, Jaime A Davidson, et al.
Diabetes Care|March 12, 2017
Assessment of Pancreas Safety in the Development Program of Once-Weekly GLP-1 Receptor Agonist DulaglutideMichael A Nauck, Jean-Louis Frossard, Jamie S Barkin, et al.
JAMA|February 20, 2002
Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trialElizabeth Barrett-Connor, Deborah Grady, Andreas Sashegyi, et al.
The Journal of Clinical Endocrinology and Metabolism|August 6, 2002
Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trialPierre D Delmas, Kristine E Ensrud, Jonathan D Adachi, et al.
Pageof 1